通过抑制eIF4E/eIF4G相互作用,发现新型的酸衍生物作为强效的抗癌剂
Binrong Yao1, Chao Zhang1, Ze Ye1
1National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China; State Key Laboratory of National Security Specially Needed Medicines, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
一种新型化合物A37通过向真核细胞启动因子4E (eIF4E) 有效地抑制癌细胞生长和瘤发育. 这种有前途的抗癌药物表现出低毒性,表明其临床应用的潜力.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 细胞启动因子4E (eIF4E) 的过度表达在许多人类癌症中很普遍.
- eIF4E是蛋白质合成的关键调节剂,也是经过验证的抗癌标.
研究的目的:
- 设计,合成和评估新型氨基醇衍生物作为潜在的eIF4E抑制剂.
- 研究化合物A37.7的抗癌活性和作用机制.
主要方法:
- 合成水inyl thiazole衍生物的合成.
- 针对各种癌细胞系 (A549,Hela,HepG2,MCF-7) 和正常细胞 (HEK-293T) 的体外抗增殖试验.
- 分子对接和表面等离子体共振 (SPR) 对于eIF4E结合亲和力.
- 西方涂抹用于分析信号通路 (Ras/MAPK/eIF4E).
- 在裸体小鼠中使用HepG2异种移植的体内疗效研究.
主要成果:
- 化合物A37对具有低细胞毒性的多个癌症细胞系表现出强大的抗增殖活性.
- A37对eIF4E蛋白具有很高的亲和力.
- A37抑制了Ras/MAPK/eIF4E信号通路,诱导了细胞亡,并减少了细胞迁移.
- 在体内,A37显著抑制了瘤生长,毒性最小.
结论:
- A37是eIF4E/eIF4G相互作用的强效和低毒性抑制剂.
- A37通过多种机制表现出显著的抗瘤作用.
- A37作为各种癌症的潜在治疗剂具有前途.
更多相关视频
08:47Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules
